Partnership to Offer Assay Development and Transfer Services

Fleet Bioprocessing and Gyros Protein Technologies AB (Uppsala) have signed a Certified Assay Transfer & Development Partner agreement, under which Fleet will provide assay development, transfer and optimisation services for the Swedish company’s Gyrolab® platform users.

The nanolitre-scale Gyrolab platforms streamline assay workflow to support rapid decision-making in drug development. Accessing the resource internally to transfer assays from existing formats to work with the automated, nanoliter-scale immunoassay systems, has however been challenging. Through this new partnership agreement, Gyrolab users worldwide can now access such services, either via Gyros Protein Technologies or by working directly with Fleet, which has extensive knowledge in all aspects of immunoassay design, development and validation.

Mark Vossenaar, VP Sales EMEA, Gyros Protein Technologies, said: “This partnership was established in response to feedback from our customer base for the need to provide support in developing, transferring and optimising assays onto the Gyrolab platform. We felt that an independent third-party specialist was best placed to provide this service, and we are confident we have chosen the ideal partner in Fleet Bioprocessing.”

Alastair Dent, Managing Director, Fleet Bioprocessing, said: “We are delighted to be working with Gyros Protein Technologies and we are already seeing great interest in the new service, with our first project well under way and many more in the pipeline.”